Page 105 - MemoriaEHD-Eng

www.ciberehd.org

• MartíNez-uña M, vareLa-rey M, CaNo a, FerNáNDez-ares L, Beraza N, aurreKoetxea i, Martí- Most relevant
Nez-arraNz i, garCía-roDríguez JL, BuQué x, Mestre D, LuKa z, WagNer C, aLoNso C, FiNNeLL
scientific
rh, Lu sC, MartíNez-ChaNtar ML, aspiChueta p, Mato JM. Excess S-adenosylmethionine
reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride
articles

synthesis.Hepatology (Baltimore, Md.). 2013;58(4):1296-305.

• vazQuez-ChaNtaDa M, goNzáLez-Lahera a, MartíNez-arraNz i, garCía-MoNzóN C, regueiro
MM, g-r JL, s Ka, M i, r-e N, L JJ, B-
arCíaoDríguezChLaNgeNeNDiBiLoDríguezzpeLetaozaNoa
NasiK K, JusteseN JM, JoergeNseN t, Witte Dr, LauritzeN t, haNseN t, peDerseN o, veyrie N,
C K, t J, t a, L M-B y, B x, a p, e-
LeMeNtorDJMaNraNearChaNDrusteLuQuespiChuetaChevarria
uraga JJ, MartíN-DuCe a, CaBaLLeria J, guaL p, Castro a, Mato JM, MartíNez-ChaNtar ML,

araNsay aM. Solute carrier family 2 member 1 is involved in the development of
nonalcoholic fatty liver disease.Hepatology (Baltimore, Md.). 2013;57(2):505-14.

• yaNg h, zheNg y, Li tW, peNg h, FerNáNDez-raMos D, MartíNez-ChaNtar ML, roJas aL, Mato

JM, Lu sC. Methionine adenosyltransferase 2B, HuR, and sirtuin 1 protein cross-talk
impacts on the effect of resveratrol on apoptosis and growth in liver cancer cells.The

Journal of biological chemistry. 2013;288(32):23161-70.

• seiJo s, LozaNo JJ, aLoNso C, reverter e, MiQueL r, aBraLDes Jg. Metabolomics discloses
potential biomarkers for the noninvasive diagnosis of idiopathic portal hypertension.
ó
Am J Gastroenterol. 2013 Jun;108(6):926-32.

• peraLta B, giL-CartoN D, Castaño-Díez D, BertiN a, BouLogNe C, oKsaNeN hM, BaMForD
Dh, a Ng. Mechanism of membranous tunnelling nanotube formation in viral
BresCia
genome delivery.PLoS biology. 2013;11(9):e1001667.

In 2013 thirty-seven people, including principal investigators and post-doctoral re-
searchers, laboratory technicians and PhD students, integrated the research force Highlights

of CIC bioGUNE-CIBERehd. Our work has been mainly integrated in Program No.

2 on Cholestasis, Metabolic Diseases and Hepatotoxicity of CIBERehd’s Strategic
Plan, although it is relevant to indicate our activity in Programs No. 5 on Gastroin-

testinal and Hepatic Oncology and No. 2 on Viral Hepatitis. It is also important to
emphasize our commitment with the development of new Omics technologies, and

with the provision of services in genomics, proteomics and metabolomics to other
ó
CIBERehd researchers. Our activity in this area is not limited to the simple pro-
vision of services, but includes other aspects as the analysis of the quality of the

data and the statistic interpretation of the results. In 2013 our group published 27

research articles, several of them in top journals such as J Clin Inves, PLoS Biol, ñ
Gastroenterology and Hepatology. In 2013 we also obtained a US patent, N0.

8,563,318 B2. This patent protects a noninvasive method for the serum diagnostic
of nonalcoholic steatohepatitis (NASH) based on a metabolic profile. This method

is presently commercialized by OWL Metabolomics, a spin off of our group. Our

research team is presently funded by the MINECO, through the Plan Nacional de 13
I+D+i, the INNPACTO program, the ISCIII-CIBER (CIBERehd) and the ISCIII-FIS, 20
T
and the Ramn y Cajal and FPI programs. We are also funded by Basque Gover- OR
áP
nment through the ETORTEK program of the Department de Economic Develop- RE
ment and Competitiveness, the Ikerbasque Foundation, and the Departments of L
A
Health and Education; and by the National Institutes of Health (NIH), the COST NU
program of the European Union, the Asociacin Espaola Contra el Cncer (AECC), N
A
and Abbott Laboratories.
D /
H
E
ER
IB
C

105